New radiation combo aims to shrink sarcomas before surgery
NCT ID NCT01659203
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two types of radiation therapy—proton beam or advanced photon (IMRT)—given before surgery for retroperitoneal sarcoma, a rare tumor deep in the abdomen. The goal is to find the highest safe dose that can be delivered to high-risk areas of the tumor while protecting healthy tissue. About 80 adults with this sarcoma will receive daily radiation for six weeks, then undergo surgery. The trial first checks safety, then measures how well the treatment controls the tumor locally.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
proton beam radiation therapy or intensity-modulated photon radiation therapy (IMRT)
What this could lead to
If successful, this could establish a safer, more effective radiation approach before surgery for retroperitoneal sarcoma, potentially reducing side effects and improving tumor control.
What could go wrong
This is an early-phase trial (Phase I/II) with only 80 participants, so results may not apply broadly. Radiation can still damage nearby organs, and the higher dose boost may increase toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETROPERITONEAL SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55902, United States
Contact Email: •••••@•••••
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Email: •••••@•••••
Contact
-
Rush University Medical Center
RECRUITINGChicago, Illinois, 60612, United States
Contact Email: •••••@•••••
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Email: •••••@•••••
-
Washington University School of Medicine Siteman Cancer Center South County
RECRUITINGSt Louis, Missouri, 63129, United States
Contact Email: •••••@•••••
-
Washington University School of Medicine Siteman Cancer Center West County
RECRUITINGCreve Coeur, Missouri, 63141, United States
Contact Email: •••••@•••••